Drug News

Added 23 hours ago Drug news

Chiesi establishes Boston unit to support treatments for rare lysosomal storage, hematological and ophthalmological disorders in the US.

Chiesi Farmaceutici has established a rare disease unit in Boston. The division will develop treatments for patients with rare lysosomal...

Added 23 hours ago Drug news

Gantenerumab arm of the phase II/III DIAN-TU-001 study did not meet its primary endpoint for early- onset Alzheimer's disease.- Roche

Roche has announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in...

Added 1 day ago Drug news

Long term data for Epsolay confirms safety profile in rosacea.- Sol-Gel Technologies

Sol-Gel Technologies announced positive topline data for its open-label, long-term safety study, evaluating Epsolay (microencapsulated benzoyl peroxide cream 5%) in...

Added 1 day ago Drug news

NICE in draft guidance does not recommend the combination of Keytruda + Inlyta to treat renal cell carcinoma. Merck Inc.+ Pfizer

The National Institute for Health and Care Excellence (NICE) has released a draft guidance rejecting MSD’s Keytruda (pembrolizumab) when used...

Added 1 day ago Drug news

Tazverik filed with FDA and given accelerated approval for follicular lymphoma.- Epizyme

Epizyme announced that the FDA has accepted for filing the company’s New Drug Application (NDA) for the accelerated approval of...

Added 1 day ago Drug news

Interim data from phase IIIb STARDUST study of Stelara shows clinical response in Crohns disease.- J&J Janssen Cilag

The Janssen Pharmaceutical Companies of Johnson & Johnson announced interim data from the Phase IIIb STARDUST study of Stelara (ustekinumab)...

Added 1 day ago Drug news

FDA requires Belviq to be withdrawn from its US market due to cancer risks. Eisai

The FDA has requested that Eisai Co. Ltd. voluntarily withdraw the obesity pills Belviq and Belviq XR (lorcaserin) from the...

Added 2 days ago Drug news

FDA grants priority review to liso cel for treatment of adult patients with relapsed or refractory large B-cell lymphoma.- BMS

Bristol-Myers Squibb announced that the FDA has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel),...

Added 2 days ago Drug news

FDA grants priority review for tucatinib + trastuzumab + capecitabine to treat locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases. Seattle Genetics

Seattle Genetics announced that the FDA has accepted for priority review the Company’s New Drug Application (NDA) for the investigational...

Added 3 days ago Drug news

CE Mark for Orsiro Mission drug-eluting stent system.- Biotronik

Biotronik has announced CE Mark certification for the Orsiro Mission drug-eluting stent (DES) system. The next generation of the company’s...

Search all news articles